You're viewing Docket Item 89.2 from the case Tummino v. Hamburg. View the full docket and case details.

Download this document:




Case 1:12-cv-00763-ERK-VVP Document 103 Filed 06/10/13 Page 1 of 2 PageID #: 2391

Case: 13-1690 Document: 89-2 Page: 1 06/11/2013 962061 2



































U.S. Department of Justice







United States Attorney
Eastern District of New York




271 Cadman Plaza East
Brooklyn, NY 11201-1820

June 10, 2013












BY ELECTRONIC COURT FILING

Honorable Edward R. Korman
Senior United States District Judge
Eastern District of New York
225 Cadman Plaza East
Brooklyn, NY 11201


Re:

Tummino v. Hamburg, No. 12-CV-0763 (ERK/VVP)


Dear Judge Korman:


We write to advise the Court that the Food and Drug Administration (FDA) and the
Department of Health and Human Services (HHS) have complied with the Court’s April 10, 2013,
judgment in the above-referenced case by granting the 2001 Citizen Petition and making Plan B
One-Step (PBOS) available over-the-counter (OTC) without age or point-of-sale restrictions as
described below. It is the government’s understanding that this course of action fully complies
with the Court’s judgment in this action. Once the Court confirms that the government’s
understanding is correct, the government intends to file with the Circuit Court notice that it is
voluntarily withdrawing its appeal in this matter.


Procedurally, FDA today has invited the sponsor of PBOS, Teva Branded Pharmaceutical
Products R&D, Inc. (Teva), to promptly submit a supplemental new drug application (SNDA) with
proposed labeling that would permit PBOS to be sold without a prescription and without age or
point-of-sale restrictions. Upon receipt of this SNDA, FDA will approve it without delay. After
FDA receives and approves Teva’s supplement, we expect the sponsors of the generic versions of
PBOS to submit appropriate amendments to their abbreviated new drug applications. If FDA
grants Teva marketing exclusivity, the scope of that exclusivity may affect the labeling that could
be approved for generic equivalents of PBOS. Further to comply with the Court’s judgment, FDA
today has issued a response to the 2001 Citizen Petition granting the petition by taking the steps
with respect to PBOS described in this letter. In accordance with this Court’s order and as
explained below, FDA will not at this time take steps to change the approval status of the two-pill
Plan B or its generic equivalents.


As the Court is aware, the Second Circuit stayed this Court’s judgment pending appeal to
the extent that this Court required FDA to make PBOS available OTC, but denied a stay to the

Case 1:12-cv-00763-ERK-VVP Document 103 Filed 06/10/13 Page 2 of 2 PageID #: 2392

Case: 13-1690 Document: 89-2 Page: 2 06/11/2013 962061 2

Hon. Edward R. Korman, United States District Judge
Tummino v. Hamburg, No. 12-CV-0763 (ERK/VVP)
June 10, 2013
Page 2

extent the Court mandated that the two-pill Plan B and its generic equivalents be made available
OTC. FDA, however, intends to comply with the Court’s order in the manner described in the
preceding paragraph because this Court’s April 10, 2013, judgment expressly authorized FDA to
comply by making PBOS and not Plan B available, if FDA believes that there is a significant
difference between Plan B and PBOS. Specifically, while the Court’s judgment directed the
defendants to “make levonorgestrel-based emergency contraceptives available without a
prescription and without point-of-sale or age restrictions within 30 days,” it also provided that
“FDA may determine whether any new labeling is reasonably necessary” and that “if the FDA
actually believes that there is any significant difference between the one- and two- pill products, it
may limit its over-the-counter approval to the one-pill product.” ECF No. 87, 04/10/13, at 1-2.
FDA continues to believe, for the reasons that the government has previously explained in its
briefs to this Court, that there are significant differences between Plan B and PBOS under FDA’s
regulations and the Federal Food, Drug, and Cosmetic Act.


It is, moreover, the PBOS application that contained actual use data specifically
addressing the ability of adolescents, including younger adolescents, to understand and follow the
directions for safe and effective use as a nonprescription product; there are fewer data available
regarding the actual use of Plan B as a nonprescription product by younger adolescents. FDA
therefore believes it is appropriate and consistent with this Court's order to comply by making
only PBOS (and not the two-pill product) available OTC for younger adolescents.














cc (by email and ECF notification):






/s/ {FILED ELECTRONICALLY}
F. FRANKLIN AMANAT (FA6117)
Senior Counsel
(718) 254-6024
[email protected]

Janet Crepps
Andrea H. Costello
Kirsten Clanton
Michael Shumsky
Steven Menashi

LORETTA E. LYNCH
United States Attorney
Eastern District of New York

We appreciate the Court’s time and continued attention to this matter.

Respectfully submitted,

By: